Klotho Peptide Fragments
unknown riskAlso: KL1 fragment · Klotho · α-Klotho anti-aging fragment
α-Klotho is an anti-aging protein that declines with age. Lower levels associate with cognitive decline, kidney disease, and cardiovascular mortality. Active KL1 fragment peptides are being developed. Phase I data exists for cognitive benefits in aging primates. Significant NIH-funded human research ongoing.
Reported Benefits
Cognitive enhancement
Primate study (2017): single klotho treatment improves cognitive performance for weeks; human trials designing.
Kidney protection
Strong observational correlation: high klotho = better kidney function; causal studies ongoing.
Longevity association
Multiple human cohorts: higher soluble klotho levels associated with reduced all-cause mortality.
Mechanism of Action
Full-length klotho acts as co-receptor for FGF23; soluble fragments modulate IGF-1/insulin signaling, Wnt, and TGF-β pathways; neuroprotective via NMDA receptor modulation; renoprotective via oxidative stress reduction.
Key Clinical Studies
Leon et al. (2017)
Controlled · Animal (rhesus macaques)
Single klotho injection improves cognitive performance for weeks in aged primates
The Longevity Protein
Klotho deficiency in mice causes premature aging; overexpression extends lifespan 20–30%. The human correlational data linking high klotho to longevity and cognitive preservation is compelling.
The challenge is peptide-based delivery — the full protein is too large for SC injection, and developing active fragments with adequate half-life is the current research focus.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Unknown
Contraindications
- •Insufficient data
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Klotho Peptide Fragments?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →